LENZ Therapeutics, Inc. OTC Markets
Equities
GRPH
US52635N1037
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.16 USD | -27.40% | -4.79% | +21.37% |
Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
-2.52% | 103B | |
+1.82% | 95.28B | |
+1.46% | 22.15B | |
-15.24% | 21.02B | |
-8.58% | 18.15B | |
-41.01% | 16.73B | |
-13.42% | 16.05B | |
+4.24% | 13.68B | |
+35.67% | 12.17B |
- Stock Market
- Equities
- LENZ Stock
- GRPH Stock
- News LENZ Therapeutics, Inc.
- BTIG Starts Graphite Bio at Buy With $18 Price Target